Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene

by | Dec 19, 2022 | News

Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS) One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational lasofoxifene versus fulvestrant Second abstract addressed patients...

Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice

by | Dec 8, 2022 | News

COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced that it...

Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen

by | Sep 15, 2022 | News

COLUMBUS, Ohio, Sept. 14, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, broadly shared a case...

© Sermonix Pharmaceuticals